Trihexyphenidyl for the Management of Dystonia in Children

Marcia L. Buck, Pharm.D., FCCP, FPPAG


Pediatr Pharm. 2011;17(6) 

In This Article

Abstract and Introduction


Trihexyphenidyl was approved by the Food and Drug Administration (FDA) on May 13, 1949 under the brand name Artane®.[1] Although indicated only for use in adults with Parkinsonism or for the control of extrapyramidal disorders caused by central nervous system drugs such as phenothiazines and thioxanthenes, it has become a common treatment for a wide variety of movement disorders.[1,2] For more than 20 years, it has been used in the treatment of dystonia in children with cerebral palsy.[4–11] In these patients, trihexyphenidyl may not only produce improvements in muscle tone, but also control of sialorrhea. This issue of Pediatric Pharmacotherapy will provide an overview of the pharmacology of trihexyphenidyl and describe the results of several recent studies of its use in children.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.